An antibody to IP-10 is a potent antagonist of cell migration in vitro and in vivo and does not affect disease in several animal models of inflammation

References

• Campanella GS, Grimm J, Manice LA, Colvin RA, Medoff BD, Wojtkiewicz GR, et al. Oligomerization of CXCL10 is necessary for endothelial cell presentation and in vivo activity. J Immunol 2006; 177(10)6991–6998
   PubMedGoogle Scholar
• Dajotoy T, Andersson P, Bjartell A, Lofdahl CG, Tapper H, Egesten A. Human eosinophils produce the T cell-attracting chemokines MIG and IP-10 upon stimulation with IFN-gamma. J Leukoc Biol 2004; 76(3)685–691
   PubMedGoogle Scholar
• Herder C, Hauner H, Kempf K, Kolb H, Skurk T. Constitutive and regulated expression and secretion of interferon-gamma-inducible protein 10 (IP-10/CXCL10) in human adipocytes. Int J Obes (Lond) 2007; 31(3)403–410
   PubMedGoogle Scholar
• Kanda N, Watanabe S. Substance P enhances the production of interferon-induced protein of 10 kDa by human keratinocytes in synergy with interferon-gamma. J Invest Dermatol 2002; 119(6)1290–1297
   PubMed Web of Science ®Google Scholar
• Narumi S, Yoneyama H, Inadera H, Nishioji K, Itoh Y, Okanoue T, et al. TNF-alpha is a potent inducer for IFN-inducible protein-10 in hepatocytes and unaffected by GM-CSF in vivo, in contrast to IL-1beta and IFN-gamma. Cytokine 2000; 12(7)1007–1016
   PubMed Web of Science ®Google Scholar
• Berthier-Vergnes O, Bermond F, Flacher V, Massacrier C, Schmitt D, Peguet-Navarro J. TNF-alpha enhances phenotypic and functional maturation of human epidermal Langerhans cells and induces IL-12 p40 and IP-10/CXCL-10 production. FEBS Lett 2005; 579(17)3660–3668
   PubMedGoogle Scholar
• Booth V, Keizer DW, Kamphuis MB, Clark-Lewis I, Sykes BD. The CXCR3 binding chemokine IP-10/CXCL10: Structure and receptor interactions. Biochemistry 2002; 41(33)10418–10425
   PubMedGoogle Scholar
• Heise CE, Pahuja A, Hudson SC, Mistry MS, Putnam AL, Gross MM, et al. Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist. J Pharmacol Exp Ther 2005; 313(3)1263–1271
   PubMedGoogle Scholar
• Aggarwal A, Agarwal S, Misra R. Chemokine and chemokine receptor analysis reveals elevated interferon-inducible protein-10 (IP)-10/CXCL10 levels and increased number of CCR5+ and CXCR3+ CD4 T cells in synovial fluid of patients with enthesitis-related arthritis (ERA). Clin Exp Immunol 2007; 148(3)515–519
   PubMedGoogle Scholar
• Agostini C, Calabrese F, Rea F, Facco M, Tosoni A, Loy M, et al. CXCR3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. Am J Pathol 2001; 158(5)1703–1711
   PubMed Web of Science ®Google Scholar
• Balashov KE, Rottman JB, Weiner HL, Hancock WW. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci USA 1999; 96(12)6873–6878
   PubMed Web of Science ®Google Scholar
• Caproni M, Cardinali C, Giomi B, Antiga E, D'Agata A, Walter S, et al. Serological detection of eotaxin, IL-4, IL-13, IFN-gamma, MIP-1alpha, TARC and IP-10 in chronic autoimmune urticaria and chronic idiopathic urticaria. J Dermatol Sci 2004; 36(1)57–59
   PubMed Web of Science ®Google Scholar
• Hanaoka R, Kasama T, Muramatsu M, Yajima N, Shiozawa F, Miwa Y, et al. A novel mechanism for the regulation of IFN-gamma inducible protein-10 expression in rheumatoid arthritis. Arthritis Res Ther 2003; 5(2)R74–R81
   Google Scholar
• Melter M, Exeni A, Reinders ME, Fang JC, McMahon G, Ganz P, et al. Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation 2001; 104(21)2558–2564
   PubMedGoogle Scholar
• Nicoletti F, Conget I, Di Mauro M, Di Marco R, Mazzarino MC, Bendtzen K, et al. Serum concentrations of the interferon-gamma-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia 2002; 45(8)1107–1110
   PubMedGoogle Scholar
• Nishioji K, Okanoue T, Itoh Y, Narumi S, Sakamoto M, Nakamura H, et al. Increase of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes. Clin Exp Immunol 2001; 123(2)271–279
   PubMedGoogle Scholar
• Reiners J, Henne T, Offner G, von Schnakenburg C, Strehlau J, Latta K, et al. Mig, IP-10, and CXCR3 gene expression is predictive for the individual response of children with chronic allograft nephropathy to mycophenolate mofetil. Transplant Proc 2002; 34(6)2217–2218
   PubMedGoogle Scholar
• Scarpini E, Galimberti D, Baron P, Clerici R, Ronzoni M, Conti G, et al. IP-10 and MCP-1 levels in CSF and serum from multiple sclerosis patients with different clinical subtypes of the disease. J Neurol Sci 2002; 195(1)41–46
   PubMedGoogle Scholar
• Dixon AE, Mandac JB, Madtes DK, Martin PJ, Clark JG. Chemokine expression in Th1 cell-induced lung injury: Prominence of IFN-gamma-inducible chemokines. Am J Physiol Lung Cell Mol Physiol 2000; 279(3)L592–L599
   Google Scholar
• Matz M, Beyer J, Wunsch D, Mashreghi MF, Seiler M, Pratschke J, et al. Early post-transplant urinary IP-10 expression after kidney transplantation is predictive of short- and long-term graft function. Kidney Int 2006; 69(9)1683–1690
   PubMed Web of Science ®Google Scholar
• Narumi S, Tominaga Y, Tamaru M, Shimai S, Okumura H, Nishioji K, et al. Expression of IFN-inducible protein-10 in chronic hepatitis. J Immunol 1997; 158(11)5536–5544
   PubMed Web of Science ®Google Scholar
• Loetscher P, Pellegrino A, Gong JH, Mattioli I, Loetscher M, Bardi G, et al. The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J Biol Chem 2001; 276(5)2986–2991
   PubMed Web of Science ®Google Scholar
• Baker MS, Chen X, Rotramel AR, Nelson JJ, Lu B, Gerard C, et al. Genetic deletion of chemokine receptor CXCR3 or antibody blockade of its ligand IP-10 modulates posttransplantation graft-site lymphocytic infiltrates and prolongs functional graft survival in pancreatic islet allograft recipients. Surgery 2003; 134(2)126–133
   PubMedGoogle Scholar
• Fife BT, Kennedy KJ, Paniagua MC, Lukacs NW, Kunkel SL, Luster AD, et al. CXCL10 (IFN-gamma-inducible protein-10) control of encephalitogenic CD4+ T cell accumulation in the central nervous system during experimental autoimmune encephalomyelitis. J Immunol 2001; 166(12)7617–7624
   PubMed Web of Science ®Google Scholar
• Fischer FR, Santambrogio L, Luo Y, Berman MA, Hancock WW, Dorf ME. Modulation of experimental autoimmune encephalomyelitis: Effect of altered peptide ligand on chemokine and chemokine receptor expression. J Neuroimmunol 2000; 110(1-2)195–208
   PubMedGoogle Scholar
• Hyun JG, Lee G, Brown JB, Grimm GR, Tang Y, Mittal N, et al. Anti-interferon-inducible chemokine, CXCL10, reduces colitis by impairing T helper-1 induction and recruitment in mice. Inflamm Bowel Dis 2005; 11(9)799–805
   PubMed Web of Science ®Google Scholar
• Medoff BD, Sauty A, Tager AM, Maclean JA, Smith RN, Mathew A, et al. IFN-gamma-inducible protein 10 (CXCL10) contributes to airway hyperreactivity and airway inflammation in a mouse model of asthma. J Immunol 2002; 168(10)5278–5286
   PubMed Web of Science ®Google Scholar
• Salomon I, Netzer N, Wildbaum G, Schif-Zuck S, Maor G, Karin N. Targeting the function of IFN-gamma-inducible protein 10 suppresses ongoing adjuvant arthritis. J Immunol 2002; 169(5)2685–2693
   PubMed Web of Science ®Google Scholar
• Sasaki S, Yoneyama H, Suzuki K, Suriki H, Aiba T, Watanabe S, et al. Blockade of CXCL10 protects mice from acute colitis and enhances crypt cell survival. Eur J Immunol 2002; 32(11)3197–3205
   PubMed Web of Science ®Google Scholar
• Liu L, Callahan MK, Huang D, Ransohoff RM. Chemokine receptor CXCR3: An unexpected enigma. Curr Top Dev Biol 2005; 68: 149–181
   PubMed Web of Science ®Google Scholar
• Khan IA, MacLean JA, Lee FS, Casciotti L, DeHaan E, Schwartzman JD, et al. IP-10 is critical for effector T cell trafficking and host survival in Toxoplasma gondii infection. Immunity 2000; 12(5)483–494
   PubMed Web of Science ®Google Scholar
• Liu MT, Keirstead HS, Lane TE. Neutralization of the chemokine CXCL10 reduces inflammatory cell invasion and demyelination and improves neurological function in a viral model of multiple sclerosis. J Immunol 2001; 167(7)4091–4097
   PubMedGoogle Scholar
• Colvin BL, Wang Z, Nakano H, Wu W, Kakiuchi T, Fairchild RL, et al. CXCL9 antagonism further extends prolonged cardiac allograft survival in CCL19/CCL21-deficient mice. Am J Transplant 2005; 5(9)2104–2113
   PubMedGoogle Scholar
• Hancock WW, Gao W, Csizmadia V, Faia KL, Shemmeri N, Luster AD. Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med 2001; 193(8)975–980
   PubMed Web of Science ®Google Scholar
• Klein RS, Izikson L, Means T, Gibson HD, Lin E, Sobel RA, et al. IFN-inducible protein 10/CXC chemokine ligand 10-independent induction of experimental autoimmune encephalomyelitis. J Immunol 2004; 172(1)550–559
   PubMed Web of Science ®Google Scholar
• Narumi S, Kaburaki T, Yoneyama H, Iwamura H, Kobayashi Y, Matsushima K. Neutralization of IFN-inducible protein 10/CXCL10 exacerbates experimental autoimmune encephalomyelitis. Eur J Immunol 2002; 32(6)1784–1791
   PubMed Web of Science ®Google Scholar
• Thomas MS, Kunkel SL, Lukacs NW. Differential role of IFN-gamma-inducible protein 10 kDa in a cockroach antigen-induced model of allergic airway hyperreactivity: Systemic versus local effects. J Immunol 2002; 169(12)7045–7053
   PubMedGoogle Scholar
• Byrne FR, Morony S, Warmington K, Geng Z, Brown HL, Flores SA, et al. CD4+ CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin. Gut 2005; 54(1)78–86
   PubMedGoogle Scholar
• Hirozane T, Matsumori A, Furukawa Y, Sasayama S. Experimental graft coronary artery disease in a murine heterotopic cardiac transplant model. Circulation 1995; 91(2)386–392
   PubMedGoogle Scholar
• Proudfoot AE, Handel TM, Johnson Z, Lau EK, LiWang P, Clark-Lewis I, et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA 2003; 100(4)1885–1890
   PubMedGoogle Scholar
• Campanella GS, Medoff BD, Manice LA, Colvin RA, Luster AD. Development of a novel chemokine-mediated in vivo T cell recruitment assay. J Immunol Meth 2008; 331(1–2)127–139
   PubMedGoogle Scholar
• Patel DD, Zachariah JP, Whichard LP. CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. Clin Immunol 2001; 98(1)39–45
   PubMed Web of Science ®Google Scholar
• Singh UP, Singh S, Taub DD, Lillard JW, Jr. Inhibition of IFN-gamma-inducible protein-10 abrogates colitis in IL-10-/- mice. J Immunol 2003; 171(3)1401–1406
   PubMed Web of Science ®Google Scholar
• Uguccioni M, Gionchetti P, Robbiani DF, Rizzello F, Peruzzo S, Campieri M, et al. Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am J Pathol 1999; 155(2)331–336
   PubMed Web of Science ®Google Scholar
• Byrne FR, Viney JL. Mouse models of inflammatory bowel disease. Curr Opin Drug Discov Devel 2006; 9(2)207–217
   PubMedGoogle Scholar
• Hancock WW, Lu B, Gao W, Csizmadia V, Faia K, King JA, et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000; 192(10)1515–1520
   PubMed Web of Science ®Google Scholar
• Zhu J, Xu ZK, Miao Y, Liu XL, Zhang H. Changes of inducible protein-10 and regulated upon activation, normal T cell expressed and secreted protein in acute rejection of pancreas transplantation in rats. World J Gastroenterol 2006; 12(26)4156–4160
   PubMedGoogle Scholar
• Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 2002; 168(7)3195–3204
   PubMed Web of Science ®Google Scholar